Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
JACC CardioOncol
; 5(1): 85-98, 2023 Feb.
Article
in En
| MEDLINE
| ID: mdl-36875913
AC-THP, doxorubicin/cyclophosphamide followed by paclitaxel/trastuzumab/pertuzumab; ACTH, doxorubicin/cyclophosphamide followed by trastuzumab/paclitaxel; ADC, antibody-drug conjugate; ADR, adverse drug reaction; AI, aromatase inhibitor; FDA, U.S. Food and Drug Administration; HER2; HF, heart failure; IC, information component; LVEF, left ventricular ejection fraction; ROR, reporting odds ratio; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; antibody-drug conjugates; heart failure; trastuzumab; tyrosine kinase inhibitors
Full text:
1
Database:
MEDLINE
Type of study:
Risk_factors_studies
Language:
En
Journal:
JACC CardioOncol
Year:
2023
Type:
Article
Affiliation country:
United States